Period:
Draw Mode:
| Volume | 4,172,340 |
|
|||||
| News | - | ||||||
| Day High | 8.92 | Low High |
|||||
| Day Low | 7.32 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| PDS Biotechnology Corporation | PDSB | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 2.08 | 30.95% | 8.80 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 8.16 | 7.32 | 8.92 | 8.56 | 6.72 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 30,645 | 4,172,340 | $ 8.25 | $ 34,420,849 | - | 2.89 - 13.65 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:59:38 | 1 | $ 8.80 | USD |
PDS Biotechnology Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 270.37M | 30.72M | 28.12M | $ - | $ - | -0.32 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 814.90k | - |
PDS Biotechnology News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PDSB Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 7.58 | 8.92 | 6.64 | 7.34 | 429,546 | 1.22 | 16.09% |
| 1 Month | 6.09 | 8.92 | 5.8601 | 6.96 | 291,674 | 2.71 | 44.5% |
| 3 Months | 7.07 | 8.92 | 5.39 | 6.55 | 339,319 | 1.73 | 24.47% |
| 6 Months | 8.59 | 13.65 | 5.39 | 8.67 | 489,781 | 0.21 | 2.44% |
| 1 Year | 5.06 | 13.65 | 2.89 | 6.86 | 584,005 | 3.74 | 73.91% |
| 3 Years | 1.23 | 17.85 | 1.12 | 6.14 | 817,035 | 7.57 | 615.45% |
| 5 Years | 8.16 | 17.85 | 0.6153 | 5.80 | 645,114 | 0.64 | 7.84% |
PDS Biotechnology Description
| PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. |